Breathe Well Live Well
The Pharma Letter |
Asthma market to remain stable over next decade, despite generic erosion
The Pharma Letter New market potential in underserved asthma population: Emerging anticytokines that are predicted to launch during the next decade will serve part of the unmet need in the severe, refractory asthma population, which is currently served by only systemic … |
View full post on asthma – Google News
The West Australian |
Prospect of generic asthma drug Advair hits Glaxo
Philly.com GlaxoSmithKline P.L.C.'s top-selling drug by far is the asthma medication Advair, which accounts for about 20 percent of company revenue, but generic competition got a bit closer to reality this week. Advair is delivered to patients through an inhaler … Mylan shares jump after FDA lays out guidelines for asthma generic FDA Offers Guidance for Advair Knockoffs Glaxo May Face Generic Advair Sooner Than Expected |
View full post on asthma – Google News
Philly.com (blog) |
Mylan shares jump after FDA lays out guidelines for asthma generic
MarketWatch (blog) Shares of Mylan Inc. jumped nearly 5% in mid-afternoon trades on Tuesday after it became clear the U.S. Food and Drug Administration's guidelines on generic forms of GlaxoSmithKline's asthma medication Advair would work in favor of Mylan, considered a … FDA issues generic guidance on GSK's top-selling asthma drug, Advair GlaxoSmithKline Shares Fall After Advair Setback GSK shares hit as Advair generic threat grows in US |
View full post on asthma – Google News
Yahoo!7 News |
FDA issues generic guidance on GSK's top-selling asthma drug, Advair
Philly.com (blog) PhillyPharma. FDA issues generic guidance on GSK's top-selling asthma drug, Advair. GlaxoSmithKline's top-selling drug by far is the asthma medication Advair, which accounts for about 20 percent of company revenue. Generic competition got a bit closer … GlaxoSmithKline Shares Fall After Advair Setback Glaxo Declines as FDA Clears Path for Advair Rivals New FDA guidance threatens GlaxoSmithKline's Advair |
View full post on asthma – Google News
|
Glenmark's Singulair generic recalled for fishy smell
FiercePharma Manufacturing It has happened again, and this time, it involves nearly 600,000 bottles of Glenmark Pharmaceuticals' generic version of the Merck ($MRK) blockbuster asthma med, Singulair. The company is voluntarily recalling 29 lots of its montelukast sodium tablets. |
View full post on asthma – Google News
|
In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin's …
Business Wire (press release) The upcoming Pharmacor advisory service entitled Asthma, which will be published soon, also finds that the overall market for asthma therapies will be relatively flat over the next decade, with sales increasing slightly by approximately $200 million … |
View full post on asthma – Google News
|
In the Asthma Drug Market, Generic Erosion Will Reduce Sales of Merck/Kyorin's …
MarketWatch (press release) The upcoming Pharmacor advisory service entitled Asthma, which will be published soon, also finds that the overall market for asthma therapies will be relatively flat over the next decade, with sales increasing slightly by approximately $200 million … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Washington Post Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill Januvia beat Wall Street's … Merck tops view, newer drugs cushion asthma drug blow Merck Q3 earnings edge up despite decline in sales Merck's Profit Rises 2.2% |
View full post on asthma – Google News
 Globe and Mail |
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …
Newser The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based in Whitehouse Station, N.J … Merck tops view, newer drugs cushion asthma drug blow Merck posts mixed results for third quarter MERCK & CO., INC. : Merck 3rd-Quarter Profit Up 2.2%; Narrows Year View |
View full post on asthma – Google News
|
Dr Reddy's launches generic anti-asthma drug in US market
Moneycontrol.com … 2012 at 20:36. Dr Reddy's launches generic anti-asthma drug in US market. Drug maker Dr Reddy's Laboratories has launched its generic Montelukast Sodium oral granules used for treating asthma and seasonal allergies in the US market. Source: PTI … |
View full post on asthma – Google News